|
|
|
|
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - BCAR3 antibody (ab65111)
(enlarge)
|
|
Western blot - BCAR3 antibody (ab65111)
(enlarge)
|
|
Immunocytochemistry/ Immunofluorescence-BCAR3 antibody(ab65111)
(enlarge)
|
|
|
|
|
Product Name
|
BCAR3 antibody
|
| |
See all BCAR3 antibodies (4)...
|
|
Product type
|
Primary antibodies
|
|
Description
|
Rabbit polyclonal to BCAR3
|
|
Immunogen
|
Synthetic peptide derived from the C-terminal of human BCAR3.
|
|
Reacts with
(species key)
|
Hu
|
|
Tested applications
(see key)
|
ELISA, ICC/IF, IHC-P, WB
|
|
|
Abreviews
|
|
|
|
Application notes
(see key)
|
Recommended dilutions
ELISA: 1/10000.
ICC/IF: Use at a concentration of 1 µg/ml.
IHC-P: 1/50 - 1/100.
WB: 1/500 - 1/1000. Detects a band of approximately 93 kDa (predicted molecular weight: 93 kDa).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
|
|
Positive control
(see definition)
|
Human colon carcinoma tissue. Extracts from HeLa, Jurkat and HUVEC cells.
|
|
Research areas
|
Tags & Cell Markers >> Cell Type Markers >> Tumor Associated
|
|
Relevance
|
BCAR3 is a component of intracellular signal transduction that causes estrogen-independent proliferation in human breast cancer cells. The protein contains a putative src homology 2 (SH2) domain, a hall mark of cellular tyrosine kinase signaling molecules, and is partly homologous to the cell division cycle protein CDC48. When overexpressed, it confers anti-estrogen resistance in breast cancer cell lines.
In breast cancer, the antiestrogen tamoxifen has been prescribed for both primary treatment and the treatment of advanced metastatic disease. Although the drug induces remission in most patients with estrogen receptor-positive disease, all patients eventually develop resistance. van Agthoven et al. (1998) applied an insertional mutagenesis strategy to a breast cancer cell line. Infected cells were subjected to tamoxifen selection, and the resistant clones were screened for a common integration site linked with antiestrogen resistance. By screening a human testis cDNA library with the integration site-specific probe, they obtained a cDNA encoding BCAR3 (breast cancer antiestrogen resistance 3). The deduced 825 amino acid BCAR3 protein contains a putative Src homology 2 (SH2) domain and sequences homologous to yeast CDC48. Northern blot analysis detected abundant expression of a 3.4kb BCAR3 transcript in heart, placenta, skeletal muscle, spleen, prostate, testis, ovary, small intestine, colon, fetal kidney, and several cancer cell lines, but not in nonmalignant breast tissue; a 6kb BCAR3 transcript was also detected in skeletal muscle and heart.
|
|
|
|
|
Database links
|
The links below go to external sites and will open in a new browser window |
|
Raised in
|
Rabbit
|
|
Clonality
|
Polyclonal
|
|
Isotype
|
IgG
|
|
Purity
|
Immunogen affinity purified
|
|
Storage buffer
|
Preservative: 0.02% Sodium Azide
Constituents: 50% Glycerol, PBS, 150mM Sodium chloride, pH 7.4 Material safety datasheets (MSDS) for this product:
Glycerol MSDS
Sodium Azide MSDS
|
|
Form
|
Liquid
|
|
Concentration
|
1.000 mg/ml
|
|
Storage instructions
|
Store at -20°C. Stable for 12 months at -20°C
|
| |
At Abcam, we have one centralized database to hold all of our product information, so that everything we know about this BCAR3 antibody is on this datasheet. But please do contact us if you would like any reassurance! |
 |
|
|
See below for BCAR3 antibody images, references, products related to ab65111 and other tools.
|
| |
BCAR3 antibody images:
|
 Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - BCAR3 antibody (ab65111)
This image shows human colon carcinoma tissue stained with ab65111 at 1/50 - 1/100 dilution; with and without the immunising peptide.
Immunohistochemistry analysis of paraffin-embedded human colon carcinoma tissue stained with BCAR3 antibody (ab65111) at 1/50 - 1/100 dilution, with (right) and without (left) the immunising peptide.
|
| |
Western blot - BCAR3 antibody (ab65111)
All lanes : BCAR3 antibody (ab65111) at 1/500 dilution
Lane 1 : extracts from HeLa cells
Lane 2 : extracts from Jurkat cells
Lane 3 : extracts from HUVEC cells
Lane 4 : extracts from HUVEC cells with immunising peptide at 5 µg
Lysates/proteins at 5 µg per lane.
Predicted band size : 93 kDa
Observed band size : 93 kDa
|
| |
Immunocytochemistry/ Immunofluorescence-BCAR3 antibody(ab65111)
ICC/IF image of ab65111 stained MCF7 cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab65111, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
|
| |
| |
|
Search PubMed (MEDLINE) for references to BCAR3
|
| |
BCAR3 antibody - more information
|
Customer reviews (feedback) regarding BCAR3 antibody |
Customer FAQs regarding BCAR3 antibody |
Protocols for BCAR3 antibody |
Price and availability of products related to BCAR3 antibody |
| |
BCAR3 antibody - related products:
|
|
|
| |
BCAR3 antibody - other tools:
|
Contact Abcam with a Technical Enquiry about BCAR3 antibody |
| |
All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Pricing information loading
